Status of non-classical mononuclear platinum anticancer drug development

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 11, 2009, Pages 1357-1366

  Zhang, Jinchao ^a   Liu, Dandan ^a   Li, Yaping ^a   Sun, Jing ^a   Wang, Liwei ^a   Zang, Aimin ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

Anticancer; Cationic platinum(II) complexes; Hypoxiaselective platinum complexes; Monofunctional platinum(II) complexes; Pt(IV) complexes; Sterically hindered platinum(II) complexes; Trans platinum(II) antitumor complexes; Tri functional platinum(II) complexes

Indexed keywords

AMINE PLATINUM COMPLEX; AMMINE PLATINUM COMPLEX; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; BIS(CARBOXYLATO)PLATINUM COMPLEX; BIS(PYRIDINE)PLATINUM; CARBOPLATIN; CISPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE; PLATINUM 1,4 DIAMINOCYCLOHEXANE; PLATINUM COMPLEX; PLATINUM DICHLORO(ISOPROPYLAMINE)(DIMETHYLAMINE); PLATINUM DICHLORO(ISOPROPYLAMINE)(ISOPROPYLAMINE); PLATINUM DICHLORO(ISOPROPYLAMINE)(PROPYLAMINE); PYRIDINE DERIVATIVE; TRIAMINE CATIONIC PLATINUM; TRIFUNCTIONAL MONONUCLEAR PLATINUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG STRUCTURE; HYPOXIA; IC 50; LIPOPHILICITY; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

AMINES; ANTINEOPLASTIC AGENTS; CATIONS; CYCLOHEXANES; ISOMERISM; OXYGEN; PLATINUM;

EID: 73349112211     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709789878169     Document Type: Short Survey

References (60)

1. Boulikas, T.; Vougiouka, M. Cisplatin and platinum drugs at the molecular level (review). Oncol. Rep., 2003, 10, 1663-82.
2. Ho, Y.P.; Au-Yeung, S.C.F.; To, K.K.W. Platinum-based anticancer agents: innovative design strategies and biological perspective. Med. Res. Rev., 2003, 23, 633-55.
3. Kostova, I. Platinum complexes as anticancer agents. Recent Pat. Anticancer Drug Discov., 2006, 1, 1-22.
4. Jakupec, M.A.; Galanski, M.; Keppler, B.K. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53.
5. Cleare, M.J.; Hoeschele, J.D. Antitumor platinum compounds. Relation between structure and activity. Plat. Met. Rev., 1973a, 17, 2-13.
6. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-66.
7. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum complexes as anti-cancer drugs. Coord. Chem. Rev., 2003, 241, 133-45.
8. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum drugs: A new paradigm in chemotherapy. Curr. Med. Chem. - Anti-Cancer Agents, 2005, 5, 267-79.
9. Versantvoort, C.H.M.; Broxterman, H.J.; Bagrij, T.R.; Scheper, J.; Twentyman, P.R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumor cell lines overexpressing multidrug resistanceassociated protein. Br. J. Cancer, 1995, 72, 82-9.
10. Pendyala, L.; Creaven, P.J.; Perez, R.; Zdanowicz, J.R.; Raghavan, D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 1995, 36, 271-8.
11. Lai, G.M.; Ozols, R.F.; Young, R.C.; Hamilton, T.C. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J. Natl. Cancer. Inst., 1989, 81, 535-9.
12. Chen, Y.; Guo, Z.; Parsons, S.; Sadler, P.J. Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complexes. Chem. Eur. J., 1998, 4, 672-6.
13. Holford, J.; Raynaud, F.; Murrer, B.A.; Grimaldi, K.; Hartley, J.A.; Abrams, M.; Kelland, L.R. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anti-Cancer Drug Des., 1998, 13, 1-18.
14. Holford, J.; Sharp, S.Y.; Murrer, B.A.; Abrams, M.; Kelland, L.R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer, 1998, 77, 366-73.
15. Sharp, S.Y.; O'Neill, C.F.; Rogers, P.; Boxall, F.E.; Kelland, L.R. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur. J. Cancer, 2002, 38, 2309-15.
16. 1'-dimethyl-2,2'-biimidazole)platinum(II). Inorg. Chem., 1996, 35, 619-27.
17. Webster, L.K.; Deacon, G.B.; Buxton, D.P.; Hillcoat, B.L.; James, A.M.; Roos, I.A.G.; Thomson, R.J.; Wakelin, L.P.G.; Williams, T.L. cis-Bis(pyridine)platinum(II) organoamides with unexpected growth inhibition properties and antitumor activity. J. Med. Chem., 1992, 35, 3349-53.
18. 3. Effect of chirality of the sulfoxide. Anti. Cancer Drug Des., 1991,6, 233-7.
19. Litters, C.L. Chemical reactions occurring between Metalcontaining antineoplastic drugs and biological molecules. Pharmacol Ther., 1988, 38, 215-51.
20. Martins, E.T.; Baruah, H.; Kramarczyk, J.; Saluta, G.; Day, C.S.; Kucera, G.L.; Bierbach, U. Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore. J. Med. Chem., 2001, 44, 4492-6.
21. Brow, J.M.; Pleatman, C.R.; Bierbach, U. Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks. Bioorg. Med. Chem. Lett., 2002, 12, 2953-5.
22. Farrell, N. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin. Cancer Investig., 1993, 11, 578-9.
23. 2(4-methylpyridine) Cl]Cl, does not form N7,N7-d(GpG) chelates with DNA. An unexpected preference for platinum binding at the 5′G in d (GpG). J. Inorg. Biochem., 1990, 40, 23-35.
24. Hollis, L.S.; Sundquist, W.I.; Burstyn, J.N.; Heiger-Bernays W. J.; Bellon S. F.; Ahmed K. J.; Amundsen A. R.; Stern E. W.; Lippard S. J. Mechanistic studies of a novel class of trisubstituted platinum (II) antitumor agents. Cancer Res., 1991, 51, 1866-75.
25. Okuno, H. Mononuclear platinum(II) complex with 2-phenylpyridine ligands showing high cytotoxicity against mouse sarcoma 180 cells acquiring high cisplatin resistance. J. Med. Chem., 2001, 44, 4661-7.
26. Zhang, C.X; Lippard, S.J. New metal complexes as potential therapeutics, Curr. Opin. Chem. Biol., 2003, 7, 481-9.
27. Zhang, J.C.; Gong, Y.Q.; Zheng, X.M.; Yang, M.S.; Cui, J.R. Synthesis, cytotoxicity and DNA binding levels of tri-functional mononuclear platinum(II) complexes. Eur. J. Med. Chem., 2008, 43, 441-7.
28. Farrell, N.; Ha, T.T.B.; Souchard, J.P.; Wimmer, F.L.; Cros, S.; Johnson, N.P. Cytostatic trans-platinum(II) complexes. J. Med. Chem., 1989, 32, 2240-1.
29. Van Beusichem, M.; Farrell, N. Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline. Crystal and molecular structure of trans- dichlorobis(thiazole)platinum(II). Inorg. Chem., 1992, 31, 634-9.
30. Farrell, N.; Kelland, L.R.; Roberts, J.D.; Van Beusichem. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. M. Cancer Res., 1992, 52, 5065-72.
31. 3, pyridine). Biochem., 1993, 32, 9632-8.
32. Farrell, N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Met. Ions Biol. Syst., 1996, 32, 603-39.
33. Murphy, R.F.; Farrell, N.; Aguila, A.; Okada, M.; Balis F.M.; Fojo, T. Accumulation of novel transplatinum complexes in cisplatin and oxaliplatin resistant cell lines overcomes resistance. Proc. Am. Assoc. Cancer Res., 2005, 46, 4109-13.
34. Coluccia, M.; Natil, G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med. Chem., 2007, 7, 111-23.
35. Ma, E.S.; Bates, W.D.; Edmunds, A.; Kelland, L.R.; Fojo, T.; Farrell, N. Enhancement of aqueous solubility and stability employing a trans acetate axis in transplana amine platinum compounds while maintaining the biological profile. J. Med. Chem., 2005, 48, 5651-4.
36. 2(amine)(isopropylamine)] compounds. Cytotoxic activity and apoptosis induction in ras-transformed cells. J. Med. Chem., 1999, 42, 4264-8.
37. 2(isopropylamine)( amine')] complexes. J. Inorg. Biochem., 1999, 77, 37-42.
38. 2(N,N-dimethylamine) (isopropylamine)] in A2780cisR ovarian tumor cells. Metal Based Drugs, 2001, 8, 29-37.
39. 2(Dimethylamine) (Isopropylamine)]. Mol. Pharmacol., 2003, 63, 933-44.
40. Prokop, R.; Kasparkova, J.; Novakova, O.; Marini, V.; Pizarro, A.M.; Navarro-Ranninger, C.; Brabec, V. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Biochem. Pharmacol., 2004, 67,1097-109.
41. Khazanov, E.; Barenholtz, Y.; Gibson, D.; Najajreh, Y. Novel apoptosis-inducing trans-platinum piperidine derivatives: Synthesis and biological characterization. J. Med. Chem., 2002, 45, 5196-204.
42. Kasparkova, J.; Marini, V.; Najajreh, Y.; Gibson, D.; Brabec, V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochem., 2003, 42, 6321-32.
43. Intini, F.P.; Boccarelli, A.; Francia, V.C.; Pacifico, C.; Sivo, M.F.; Natile, G.; Giordano, D.; De Rinaldis, P.; Coluccia, M. Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties. J. Biol. Inorg. Chem., 2004, 9, 768-80.
44. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggiò, M.A.; Giordano, D.; Intini, F.P.; Caputo, P.A.; Natile, G. A transplatinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem., 1993, 36, 510-2.
45. Coluccia, M.; Boccarelli, A.; Mariggiò, M.A.; Caputo, P.A.; Intini, F.P.; Natile, G. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem. Biol. Interact., 1995, 98, 251-66.
46. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol. Pharmacol., 2000, 58, 1525-35.
47. Liu, Y.; Sivo, M.F.; Natile, G.; Sletten, E. Antitumor trans platinum adducts of GMP and AMP. Metal Based Drugs, 2000, 7, 169-76.
48. Boccarelli, A.; Intini, F.P.; Sasanelli, R.; Sivo, M.F.; Coluccia, M.; Natile, G. Synthesis and in vitro antitumor activity of platinum acetonimine complexes. J. Med. Chem., 2006, 49, 829-37.
49. Orr, R.M.; O'Neill, C.F.; Nicolson, MC.; Barnard, C.G.J.; Murrer, B.A.; Giandomenico, C.M.; Vollano, J.F.; Harrap, K.P.. Evaluation of novel amine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br. J. Cancer, 1994, 70, 415-20.
50. Kelland, L.R.; Murrer, B.A.; Abel, G.; Giandomenico, C.M.; Mistry, P.; Harrap, K.R. Amine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 1992, 52, 822-8.
51. Yoshida, M.; Khokhar, A.R.; Siddik, Z.H. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/ cycloalkylamine-platinum(IV) complexes in tumor cells. Resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexane- tetrachloroplatinum(IV). Cancer Res., 1994, 54, 4691-7.
52. Goddard, P.M.; Orr, R.M.; Valenti, M.R.; Barnard, C.F.J.; Murrer, B.A.; Kelland, L.R.; Harrap, K.R. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Anticancer Res., 1996, 16, 33-8.
53. Yamashita, T.; Hirose, J.; Noji, M.; Saito, R.; Tomida, H.; Kidani, Y. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand. Biol. Pharm. Bull., 1993, 16, 1014-8.
54. Khokhar, A.R.; Al-Baker, S.; Siddik, Z.H. Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. J Inorg. Biochem., 1994, 54, 39-47.
55. Ali Khan, S. R.; Huang, S.; Shamsuddin, S.; Inutsuka, S.; Whitmire, K. H.; Siddik, Z.H.; Khokhar, A. R. A. R. Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate) 2Cl2]. Bioorg. Med. Chem., 2000, 8, 515-21.
56. Reithofer, M. R.; Schwarzinger, A.;Valiahdi, S. M.; Galanski, M.; Jakupec, M.A.; Keppler, B. K. Novel bis(carboxylato)dichlorido( ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. J. Inorg. Biochem., 2008, 102, 2072-7.
57. Farrell, N. Metal complexes as rediosensitizers. Prog. Clin. Biol. Med., 1989, 10, 90-109.
58. 3)(radiosensitizer)]. J.Chem. Soc. Chem. Commun., 1987, 1043-4.
59. 3)L],L= misonidazole, metronidazole. Anti Cancer Drug Des., 1990, 5, 121-8.
60. 2Im)]. The crystal and molecular structure of cis-amminedichloro (1-{N-(2-hydroxyethyl)-acetamido}-2- nitromidazole) platinum (II). Inorg. Chem., 1991, 30, 4531-35.